A summary of recent safety letters sent to relevant healthcare professionals
In October 2016, the following letters were sent to relevant healthcare professionals:
- Flolan (epoprostenol): new thermostable formulation (solvent pH 12) available from October 2016, with differences in storage and administration from previous formulation (pH 10.5)
- Teva levothyroxine: reintroduction to market and introduction of new tablet strengths (letter for Clinical Commissioning Groups, and for pharmacists and dispensers); see also further information here
- Blincyto▼ (blinatumomab): cases of pancreatitis
Article citation: Drug Safety Update volume 10 issue 4, November 2016: 3.